Cellular and Gene Therapy Products
Stories
-
FDA releases final guidance on potency assurance for cellular and gene therapy products
The notice, published November 3, 2026, announces the availability of the guidance with docket number FDA-2023-D-4299. It recommends a comprehensive strategy grounded in quality risk management for both investigational and licensed CGT products.